八反田 文彦 (ハツタンダ フミヒコ)

北海道大学病院 中央診療施設等助教

研究者基本情報

■ 学位
  • 医学博士, 北海道大学, 2018年03月
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 90978230
ORCID IDJ-Global ID■ 研究キーワード・分野
研究キーワード
  • 多発性嚢胞腎
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2025年04月 - 現在
    北海道大学病院, 血液浄化部, 助教, 日本国
  • 2024年04月 - 2025年03月
    北海道大学病院, リウマチ・腎臓内科, 特任助教, 日本国
  • 2018年07月 - 2020年06月
    札幌市立病院, 腎臓内科, 医員, 日本国
  • 2014年04月 - 2018年06月
    北海道大学病院, 内科Ⅱ, 大学院生, 日本国
  • 2013年07月 - 2014年03月
    苫小牧市立病院, 内科, 後期研修医, 日本国
  • 2012年04月 - 2013年06月
    釧路赤十字病院, 内科, 後期研修医, 日本国
  • 2011年04月 - 2012年03月
    北海道大学, 初期研修医, 日本国
  • 2010年04月 - 2011年03月
    砂川市立病院, 初期研修医, 日本国
委員歴
  • 2022年 - 現在
    厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業) 難治性腎障害に関する調査研究班, 疾患登録・調査研究分科会 多発性嚢胞腎ワーキンググループ

研究活動情報

■ 論文
  • Successful treatment with clofazimine for macrolide-resistant Mycobacterium abscessus infection in a peritoneal dialysis patient: A case report and literature review.
    Mizuki Kimura; Kanako Watanabe-Kusunoki; Mina Eguchi; Fumihiko Hattanda; Daigo Nakazawa; Saori Nishio; Takayuki Hirose; Keisuke Kamada; Tatsuya Atsumi
    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 8968608261432158, 8968608261432158, 2026年03月16日, [国際誌]
    英語, 研究論文(学術雑誌), Nontuberculous mycobacteria are rare but serious pathogens in peritoneal dialysis (PD)-associated infections. Mycobacterium abscessus (M. abscessus) is usually resistant to standard anti-tuberculosis drugs. Macrolide antibiotics are key drugs for treating M. abscessus, but macrolide-resistant strains pose particular challenges, and an optimal antimicrobial treatment strategy or duration has not been established for M. abscessus PD-associated infections. We report a case of a 63-year-old man on PD who developed persistent purulent discharge from his PD catheter exit site. Skin swab culture identified macrolide-resistant M. abscessus, with imaging confirming inflammation along the catheter tunnel. These findings led to the diagnosis of M. abscessus PD catheter tunnel infection, with peritonitis excluded. Initial management included early catheter removal, extensive surgical debridement, and 6 weeks of combination antibiotic therapy, including imipenem-cilastatin, amikacin, and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin, and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine, and sitafloxacin for 4 months. This approach achieved sustained clinical cure without recurrence at 14 months of follow-up. Based on a literature review of 67 cases of M. abscessus PD-associated infections, all six cases treated with clofazimine achieved clinical cure, but there were no reports on cases of macrolide-resistant M. abscessus treated with clofazimine. Our case represents the first successful clofazimine treatment of macrolide-resistant M. abscessus PD-associated infection, demonstrating clofazimine as a potentially effective oral antibiotic option in combination therapy, particularly in macrolide-resistant cases with limited therapeutic options.
  • The safety and effectiveness of transcatheter renal arterial embolization with tris-acryl gelatin microspheres in hemodialysis patients with autosomal dominant polycystic kidney disease.
    Fumihiko Hattanda; Yusuke Sakuhara; Yusuke Watanabe; Daigo Nakazawa; Yoichi M Ito; Norihiro Sato; Tatsuya Atsumi; Saori Nishio
    Clinical and experimental nephrology, 30, 1, 126, 134, 2026年01月, [国内誌]
    英語, 研究論文(学術雑誌), PURPOSE: To investigate the safety and effectiveness of transcatheter arterial embolization (TAE) with tris-acryl gelatin microspheres in patients with symptomatic enlarged polycystic kidneys (PCKs). MATERIAL AND METHODS: This prospective study was planned as a safety trial for patients with symptomatic enlarged PCKs who complained of a marked abdominal distention, gastroesophageal reflux, or abdominal pain. We then assessed renal volume reduction and improvement in clinical symptoms as secondary endpoints. The patients after induction of dialysis therapy (urinary volume less than 500 mL per day) were included. Bilateral renal TAE with tris-acryl gelatin microspheres injection followed by metallic coils placement was performed, and adverse events, clinical symptoms, abdominal circumference, blood pressure, dry weight and laboratory data were evaluated at 1, 3, 6 and 12 months after TAE. Each kidney volume was calculated before TAE and at 3, 6 and 12 months after TAE. RESULTS: Six kidneys of three patients (65-, 58- and 54 years women) were treated. All three patients experienced abdominal pain, vomiting and inflammatory reactions immediately after TAE; however, abdominal pain and vomiting resolved within their hospitalization period, and inflammatory reactions improved during the follow-up period in all patients. Accelerated renal anemia was ameliorated by temporary blood transfusions and increased doses of erythropoiesis-stimulating agent or darbepoetin alpha during dialysis. The mean kidney volume was 3885 mL before TAE and 3025, 2320 and 1832 mL at 3, 6 and 12 months after TAE, respectively. CONCLUSION: Renal TAE with tris-acryl gelatin microspheres is considered a safe and effective treatment for symptomatic enlarged PCKs. TRIAL REGISTRATION: This clinical trial was registered with the University Hospital Medical Information Network (UMIN) under the registration number UMIN000016576.
  • 修正大血管転位症による心不全に対して腹膜透析を導入した一例
    一条 昌裕; 竹中 駿; 中沢 大悟; 楠 加奈子; 八反田 文彦; 山澤 弘州; 西尾 妙織; 渥美 達也
    日本腎臓学会誌, 67, 6-E, 778, 778, (一社)日本腎臓学会, 2025年09月
    日本語
  • 関節リウマチ経過中にIgA沈着型膜性腎症および巨細胞性動脈炎を併発した一例
    河田 喜大; 松岡 奈央子; 竹山 脩平; 楠 加奈子; 八反田 文彦; 中沢 大悟; 辻 隆裕; 西尾 妙織; 渥美 達也
    日本腎臓学会誌, 67, 6-E, 833, 833, (一社)日本腎臓学会, 2025年09月
    日本語
  • 抗ネフリン抗体価と巣状分節性糸球体硬化症移植後再発の経過に乖離を認めた一例
    伊藤 康裕; 江口 みな; 楠 加奈子; 八反田 文彦; 中沢 大悟; 堀田 紀世彦; 白井 陽子; 三浦 健一郎; 服部 元史; 西尾 妙織; 渥美 達也
    日本腎臓学会誌, 67, 6-E, 843, 843, (一社)日本腎臓学会, 2025年09月
    日本語
  • 摂食障害による低カリウム血症で慢性尿細管間質性腎炎と尿細管に石灰沈着を来した一例
    神 英里; 江口 みな; 楠 加奈子; 八反田 文彦; 中沢 大悟; 小川 弥生; 入宇田 智子; 西尾 妙織; 渥美 達也
    日本腎臓学会誌, 67, 6-E, 855, 855, (一社)日本腎臓学会, 2025年09月
    日本語
  • Development and validation of a simplified CT volumetry for estimating total liver volume in patients with autosomal dominant polycystic kidney and liver disease.
    Fumihiko Hattanda; Yusuke Watanabe; Yusuke Sakuhara; Shun Takenaka; Tauro Kawamura; Naoko Matsuoka; Daigo Nakazawa; Yoichi M Ito; Hiroshi Kondo; Shin Goto; Yoshitaka Isaka; Ken Tsuchiya; Toshio Mochizuki; Satoru Muto; Haruna Kawano; Tatsuya Atsumi; Saori Nishio
    Clinical and experimental nephrology, 2025年07月23日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Accurate liver volume measurement is crucial for evaluating liver cyst severity and treatment efficacy in polycystic liver disease (PLD). Previous methods are impractical because they are time-consuming and labor-intensive. This study developed and validated two simplified CT imaging methods: the Bi-axial Simplified Measurement Method (BASiM) and the Quadri-dimensional Simplified Measurement Method (QDSiM). METHODS: This retrospective study analyzed 76 CT images from 26 PLD patients who underwent transarterial hepatic artery embolization (TAE). Images were obtained before TAE, 24 weeks after TAE and during the follow-up period. Liver volumes were measured using semi-automatic volumetry, BASiM, and QDSiM. BASiM calculates liver volume based on cranio-caudal, anterior-posterior, and medial-lateral dimensions, while QDSiM divides the liver into left- and right-side sections. This study assessed inter-assessor reliability, measurement accuracy, volume change rate, and calculation times. RESULTS: BASiM demonstrated strong inter-assessor reliability (intraclass correlation coefficient [ICC]: 0.991, 95% confidence interval [CI] 0.986-0.994) superior to QDSiM (ICC: 0.851, 95% CI 0.205-0.949). Calibrated liver volumes using BASiM and QDSiM were consistent with semi-automatic volumetry (ICC: 0.924, 95% CI 0.858 to 0.957, and ICC: 0.934, 95% CI 0.806-0.970, respectively). BASiM showed better alignment with volume changes (ICC: 0.835, 95% CI 0.537-0.927) compared to QDSiM (ICC: 0.607, 95% CI 0.203-0.800) and required less measurement time (61 ± 4 s vs. 107 ± 9 s, p < 0.01). CONCLUSION: BASiM provided superior reliability, accuracy, and efficiency for liver volume measurement in PLD, thus useful for the clinical management of PLD.
  • Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy.
    Shun Takenaka; Fumihiko Hattanda; Takuro Kawamura; Kanako Watanabe-Kusunoki; Daigo Nakazawa; Hiraku Kameda; Olga Amengual; Tatsuya Atsumi; Saori Nishio
    CEN case reports, 2025年06月27日, [国内誌]
    英語, 研究論文(学術雑誌), A 35-year-old female was diagnosed with autosomal dominant polycystic kidney disease (ADPKD) in 2002 and referred to the Nephrology department of our hospital for follow-up and management. Treatment with tolvaptan was started in 2016, which failed to reduce her total kidney volume (TKV) and slow the decline in kidney function. In 2018, she experienced bitemporal hemianopia. Examination revealed enlarged fingers, characteristic facial features, and elevated serum insulin-like growth factor 1 (IGF-1) and growth hormone (GH) levels. A pituitary tumor was identified through the brain, and she was subsequently diagnosed with acromegaly. Lanreotide treatment was initiated, effectively reducing IGF-1 and GH serum levels and TKV within six months. After transsphenoidal surgery, lanreotide was discontinued. However, her oral glucose tolerance test after surgery did not show remission (GH nadir > 0.4 ng/mL), and serum GH levels gradually increased. Furthermore, TKV increased and kidney function decreased rapidly. Lanreotide treatment was restarted, resulting in further TKV reduction, suppression of liver volume enlargement and slowing kidney function decline. Compared to tolvaptan, the evidence for the effectiveness of somatostatin analogs in reducing TKV in ADPKD is not sufficiently established. Our case demonstrates that lanreotide effectively suppressed the progression of TKV, liver volume and kidney dysfunction with correlation to IGF-1 or GH in a patient with ADPKD. Our experience indicates that elevated levels of IGF-1 or GH may contribute to increased kidney and liver volume. Herein, we report the first case of tolvaptan-resistant ADPKD with concomitant acromegaly successfully managed with lanreotide.
  • Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5.
    Akinari Sekine; Junichi Hoshino; Toshio Mochizuki; Shinya Nakatani; Saori Nishio; Tatsuya Suwabe; Hiroki Hayashi; Hirayasu Kai; Koichi Seta; Fumihiko Hattanda; Sumi Hidaka; Kazushige Hanaoka; Mahiro Kurashige; Hiroshi Kataoka; Kiyotaka Uchiyama; Keiji Shimazu; Eiji Ishikawa; Yosuke Shimada; Haruna Kawano; Ken Tsuchiya; Shigeo Horie; Ichiei Narita; Yoshitaka Isaka; Satoru Muto
    Kidney international reports, 10, 6, 1864, 1873, 2025年06月, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In Japan, the therapeutic dose of tolvaptan (60-120 mg/d) must be discontinued at chronic kidney disease stage G5 (CKD-G5), eGFR < 15 ml/min per 1.73 m2. However, low-dose tolvaptan (≤ 15 mg/d) can be continued in CKD-G5 patients with heart failure complicated by kidney failure. METHODS: This was a Japanese nation-wide, multicenter, retrospective observational study. Between May 2014 and September 2019, 110 patients with ADPKD developed CKD-G5 were included (data: previous 10 years). Participants were categorized into 3 groups: the tolvaptan continued group (received tolvaptan before CKD-G5 and reduced the dose to ≤ 15 mg at CKD-G5, N = 14), the tolvaptan discontinued group (received tolvaptan before CKD-G5 but discontinued at CKD-G5, N = 13), and the non-tolvaptan group (never received tolvaptan, N = 83). RESULTS: The eGFR slope remained stable before and during CKD-G5 in the non-tolvaptan group. In the tolvaptan discontinued group, the eGFR slope was accelerated from before (-3.3 [-4.3, -2.5] ml/min per 1.73 m2/yr) to during CKD-G5 (-5.3 [-6.7, -3.8]). However, in the tolvaptan continued group, the eGFR slope did not change from before (-3.9 [-5.4, -2.6]) to during CKD-G5 (-3.8 [-5.4, -3.4]). Compared with the tolvaptan continued group, the eGFR slope worsened significantly from before to during CKD-G5 in the tolvaptan discontinued group (P = .006). CONCLUSION: Continuation of low-dose tolvaptan may be effective in suppressing kidney function deterioration in ADPKD patients with CKD-G5. A clinical trial is needed to evaluate its efficacy and safety.
  • Tubulointerstitial nephritis with IgM-positive plasma cells complicated by liver failure.
    Takashi Kudo; Daigo Nakazawa; Saori Nishio; Fumihiko Hattanda; Yusho Ueda; Junpei Yoshikawa; Satoka Shiratori-Aso; Sari Iwasaki; Takahiro Tsuji; Yasuni Nakanuma; Goki Suda; Koji Ogawa; Naoya Sakamoto; Tatsuya Atsumi
    CEN case reports, 14, 2, 253, 260, 2025年04月, [国内誌]
    英語, 研究論文(学術雑誌), Tubulointerstitial nephritis (TIN) is characterized by inflammation of the renal interstitium with the infiltration of immune cells, mainly consisting of T cells. Recently, patients with TIN with the predominant infiltration of immunoglobulin M (IgM)-positive plasma cells were reported, coined IgMPC-TIN. Here we report the case of a 70-year-old woman diagnosed with Fanconi syndrome and renal tubular acidosis. Renal biopsy revealed IgMPC-TIN. Her renal dysfunction and clinical findings improved after corticosteroid therapy. However, the patient died of progressive liver failure and spontaneous bacterial peritonitis. In laboratory tests, viral hepatitis was excluded, and autoantibodies associated with liver diseases were negative. Generally, IgMPC-TIN is often complicated by primary biliary cholangitis (PBC), whereas her autopsy revealed the local infiltration of IgM-positive plasma cells, obliterative portal venopathy, and nodular regenerative hyperplasia in liver. This case is the first demonstration that IgMPC-TIN is also seen in liver disease with nodular regenerative hyperplasia, although IgMPC-TIN is more common in anti-M2 antibody-positive disease.
  • Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis
    Yusho Ueda; Daigo Nakazawa; Saori Nishio; Satoka Shiratori-Aso; Takashi Kudo; Atsuko Miyoshi-Harashima; Kanako Watanabe-Kusunoki; Fumihiko Hattanda; Sari Iwasaki; Takahiro Tsuji; Utano Tomaru; Yasuaki Aratani; Mamiko Yamamoto; Akihiro Ishizu; Tatsuya Atsumi
    Kidney International, 105, 6, 1291, 1305, Elsevier BV, 2024年06月
    研究論文(学術雑誌)
  • Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP)
    Shinya Nakatani; Haruna Kawano; Mai Sato; Junichi Hoshino; Saori Nishio; Kenichiro Miura; Akinari Sekine; Tatsuya Suwabe; Sumi Hidaka; Hiroshi Kataoka; Eiji Ishikawa; Keiji Shimazu; Kiyotaka Uchiyama; Takuya Fujimaru; Tomofumi Moriyama; Mahiro Kurashige; Wataru Shimabukuro; Fumihiko Hattanda; Tomoki Kimura; Yusuke Ushio; Shun Manabe; Hirofumi Watanabe; Michihiro Mitobe; Koichi Seta; Yosuke Shimada; Hirayasu Kai; Kan Katayama; Daisuke Ichikawa; Hiroki Hayashi; Kazushige Hanaoka; Toshio Mochizuki; Koichi Nakanishi; Ken Tsuchiya; Shigeo Horie; Yoshitaka Isaka; Satoru Muto; Amane Endo; Shiho Makabe; Seiji Tanaka; Tadashi Otsuka; Takeshi Yamada; Takehiko Wada; Yoshinobu Nagaoka; Tanaka Hiroshi; Noriko Sugawara; Hiroaki Tamura; Ogino Daisuke; Yuji Kano; Shuichiro Fujinaga; Yuko Akioka; Ryugo Hiramoto; Ken Kawamura; Yuko Hamasaki; Riku Hamada; Takeshi Yanagihara; Aya Inaba; Hirotsugu Kitayama; Masaki Yamamoto; Yoshimitsu Goto; Naoya Fujita; Eiji Matsukuma; Toshihiro Sawai; Rika Fujimaru; Masashi Nishida; Takahisa Yoshikawa; Kandai Nozu; Hiroshi Kaito; Naohiro Kamiyoshi; Tomoaki Ishikawa; Yuko Shima; Toshiyuki Ota; Kei Nishiyama; Yoshitsugu Kaku; Hitoshi Nakazato; Shinichi Shiona; Takao Konomoto; Akinori Miyazono; Tomoo Kise; Kenichi Maruyama; Ayano Inui; Hideaki Okajima; Takuo Kubota; Yukihiro Inomata; Toshifumi Yodoshi
    Clinical and Experimental Nephrology, 28, 1004, 1015, Springer Science and Business Media LLC, 2024年05月11日
  • Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD
    Shin-Ichi Mae; Fumihiko Hattanda; Hiroyoshi Morita; Aya Nozaki; Naoko Katagiri; Hanako Ogawa; Kaori Teranaka; Yu Nishimura; Aoi Kudoh; Sanae Yamanaka; Kyoko Matsuse; Makoto Ryosaka; Akira Watanabe; Tomoyoshi Soga; Saori Nishio; Kenji Osafune
    Cell Reports, 42, 113431, Elsevier BV, 2023年12月01日
    In autosomal dominant polycystic kidney disease (ADPKD), renal cyst lesions predominantly arise from collecting ducts (CDs). However, relevant CD cyst models using human cells are lacking. Although previous reports have generated in vitro renal tubule cyst models from human induced pluripotent stem cells (hiPSCs), therapeutic drug candidates for ADPKD have not been identified. Here, by establishing expansion cultures of hiPSC-derived ureteric bud tip cells, an embryonic precursor that gives rise to CDs, we succeed in advancing the developmental stage of CD organoids and show that all CD organoids derived from PKD1
  • Inhibition of Toll-like receptor 4 and Interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury
    Daigo Nakazawa; Yohei Takeda; Masatoshi Kanda; Utano Tomaru; Haruko Ogawa; Takashi Kudo; Satoka Shiratori-Aso; Kanako Watanabe-Kusunoki; Yusho Ueda; Atsuko Miyoshi; Fumihiko Hattanda; Saori Nishio; Ryo Uozumi; Akihiro Ishizu; Tatsuya Atsumi
    Cell Death Discovery, 9, 1, Springer Science and Business Media LLC, 2023年08月10日
    研究論文(学術雑誌), AbstractAcute kidney injury (AKI) is a common and severe complication of the coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly affects the glomerular and tubular epithelial cells to induce AKI; however, its pathophysiology remains unclear. Here, we explored the underlying mechanisms and therapeutic targets of renal involvement in COVID-19. We developed an in vitro human kidney cellular model, including immortalized tubular epithelial and endothelial cell lines, demonstrating that SARS-CoV-2 directly triggers cell death. To identify the molecular targets in the process of SARS-CoV-2-mediated cell injury, we performed transcriptional analysis using RNA sequencing. Tubular epithelial cells were more prone to dying by SARS-CoV-2 than endothelial cells; however, SARS-CoV-2 did not replicate in renal cells, distinct from VeroE6/transmembrane protease serine 2 cells. Transcriptomic analysis revealed increased inflammatory and immune-related gene expression levels in renal cells incubated with SARS-CoV-2. Toll-like receptor (TLR) 3 in renal cells recognized viral RNA and underwent cell death. Furthermore, analysis of upstream regulators identified several key transcriptional regulators. Among them, inhibition of the interleukin-1 receptor (IL-1R) and TLR4 pathways protects tubular epithelial and endothelial cells from injury via regulation of the signal transducer and activator of transcription protein-3/nuclear factor-kB pathway. Our results reveal that SARS-CoV-2 directly injures renal cells via the proinflammatory response without viral replication, and that IL-1R and TLR4 may be used as therapeutic targets for SARS-CoV-2 mediated kidney injury.
  • Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease
    Hiroshi Kataoka; Yosuke Shimada; Tomonori Kimura; Saori Nishio; Shinya Nakatani; Toshio Mochizuki; Ken Tsuchiya; Junichi Hoshino; Fumihiko Hattanda; Haruna Kawano; Kazushige Hanaoka; Sumi Hidaka; Daisuke Ichikawa; Eiji Ishikawa; Kiyotaka Uchiyama; Hiroki Hayashi; Shiho Makabe; Shun Manabe; Michihiro Mitobe; Akinari Sekine; Tatsuya Suwabe; Hirayasu Kai; Mahiro Kurashige; Koichi Seta; Keiji Shimazu; Tomofumi Moriyama; Mai Sato; Tadashi Otsuka; Kan Katayama; Wataru Shimabukuro; Takuya Fujimaru; Kenichiro Miura; Koichi Nakanishi; Shigeo Horie; Kengo Furuichi; Hirokazu Okada; Ichiei Narita; Satoru Muto
    Clinical and Experimental Nephrology, 27, 10, 809, 818, Springer Science and Business Media LLC, 2023年06月27日
    研究論文(学術雑誌), Clinical practice guidelines recommend antihypertensive and tolvaptan therapies for patients with autosomal dominant polycystic kidney disease (ADPKD) in Japan. However, tolvaptan therapy may pose an economic burden. The Japanese Ministry of Health, Labour and Welfare supports patients with intractable diseases. This study aimed to confirm the impact of the intractable disease system in Japan on the clinical treatment of ADPKD.We analyzed the data of 3768 patients with ADPKD having a medical subsidy certificate from the Japanese Ministry of Health, Labour and Welfare in 2015-2016. The following quality indicators were use: the adherence rate to the 2014 clinical practice guideline for polycystic kidney disease (prescription rates of antihypertensive agents and tolvaptan in this cohort) and the number of Japanese patients with ADPKD nationwide started on renal replacement therapy in 2014 and 2020.Compared with new applications from 2015 to 2016, the prescription rates of antihypertensives and tolvaptan for the indicated patients at the 2017 renewal application increased by 2.0% (odds ratio = 1.41, p = 0.008) and 47.4% (odds ratio = 10.1, p  0.001), respectively. These quality indicators improved with antihypertensive treatment, especially in patients with chronic kidney disease stages 1-2 (odds ratio = 1.79, p = 0.013) and in those aged  50 years (odds ratio = 1.70, p = 0.003). The number of patients with ADPKD who were started on renal replacement therapy in Japan decreased from 999 in 2014 to 884 in 2020 in the nationwide database (odds ratio = 0.83, p  0.001).The Japanese public intractable disease support system contributes to improvement of ADPKD treatment.
  • HIF-PHD阻害薬が常染色体顕性多発性嚢胞腎の肝嚢胞形成に与える影響
    竹中 駿; 西尾 妙織; 川村 拓朗; 三好 敦子; 上田 雄翔; 麻生 里佳; 松岡 奈央子; 八反田 文彦; 中沢 大悟; 渥美 達也
    日本臨床分子医学会学術総会プログラム・抄録集, 58回, 54, 54, 日本臨床分子医学会, 2023年04月
    日本語
  • Transcriptional dynamics of granulocytes in direct response to incubation with SARS‐CoV‐2
    Daigo Nakazawa; Yohei Takeda; Masatoshi Kanda; Utano Tomaru; Haruko Ogawa; Takashi Kudo; Satoka Shiratori‐Aso; Kanako Watanabe‐Kusunoki; Yusho Ueda; Atsuko Miyoshi; Fumihiko Hattanda; Saori Nishio; Ryo Uozumi; Akihiro Ishizu; Tatsuya Atsumi
    FEBS Open Bio, 13, 1, 60, 71, Wiley, 2022年11月28日
    研究論文(学術雑誌), Severe coronavirus disease 2019 (COVID‐19) is characterized by acute respiratory distress syndrome and multiple organ dysfunction, in which the host immune response plays a pivotal role. Excessive neutrophil activation and subsequent superfluity of neutrophil extracellular traps (NETs) can lead to tissue damage, and several studies have shown the involvement of neutrophils in severe COVID‐19. However, the detailed responses of each neutrophil subset to SARS‐CoV‐2 infection has not been fully described. To explore this issue, we incubated normal‐density granulocytes (NDGs) and low‐density granulocytes (LDGs) with different viral titers of SARS‐CoV‐2. NDGs form NETs with chromatin fibers in response to SARS‐CoV‐2, whereas LDGs incubated with SARS‐CoV‐2 display a distinct morphology with condensed nuclei and moderate transcriptional changes. Based on these transcriptional changes, we suggest that AGO2 possibly plays a role in LDG regulation in response to SARS‐CoV‐2.
  • Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Akinari Sekine; Sumi Hidaka; Tomofumi Moriyama; Yasuto Shikida; Keiji Shimazu; Eiji Ishikawa; Kiyotaka Uchiyama; Hiroshi Kataoka; Haruna Kawano; Mahiro Kurashige; Mai Sato; Tatsuya Suwabe; Shinya Nakatani; Tadashi Otsuka; Hirayasu Kai; Kan Katayama; Shiho Makabe; Shun Manabe; Wataru Shimabukuro; Koichi Nakanishi; Saori Nishio; Fumihiko Hattanda; Kazushige Hanaoka; Kenichiro Miura; Hiroki Hayashi; Junichi Hoshino; Ken Tsuchiya; Toshio Mochizuki; Shigeo Horie; Ichiei Narita; Satoru Muto
    Journal of Clinical Medicine, 11, 21, 6528, MDPI AG, 2022年11月03日
    研究論文(学術雑誌), Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.
  • ステロイドにミゾリビンを併用し寛解を達成したC1q腎症の一例
    清水 哲夫; 竹中 駿; 松岡 奈央子; 麻生 里佳; 八反田 文彦; 中沢 大悟; 西尾 妙織; 渥美 達也
    日本腎臓学会誌, 64, 6-E, 562, 562, (一社)日本腎臓学会, 2022年10月
    日本語
  • IgM陽性形質細胞を伴う尿細管間質性腎炎の一例
    今井 薫子; 西尾 妙織; 八反田 文彦; 辻 隆裕; 麻生 里佳; 松岡 奈央子; 中沢 大悟; 渥美 達也
    日本腎臓学会誌, 64, 6-E, 577, 577, (一社)日本腎臓学会, 2022年10月
    日本語
  • A Novel Antineutrophil Extracellular Trap Antibody Targeting Myosin Light Chain 6 in Microscopic Polyangiitis
    Yoshinari, Miku; Hattanda, Fumihiko; Nishibata, Yuka; Masuda, Sakiko; Nakazawa, Daigo; Tomaru, Utano; Ishizu, Akihiro
    The Journal of Rheumatology, 49, 11, 1286, 1288, 2022年06月15日
    英語, 研究論文(学術雑誌)
  • Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study
    Satoka Shiratori-Aso; Daigo Nakazawa; Saori Nishio; Yusho Ueda; Mina Eguchi; Ai Yokoyama; Junpei Yoshikawa; Takashi Kudo; Kanako Watanabe-Kusunoki; Sayo Takeda-Otera; Junya Yamamoto; Naoko Matsuoka; Nobuharu Kaneshima; Fumihiko Hattanda; Sari Iwasaki; Takahiro Tsuji; Yuichiro Fukasawa; Tatsuya Atsumi
    Frontiers in Medicine, 9, Frontiers Media SA, 2022年02月25日
    研究論文(学術雑誌), BackgroundAutoimmune tubulointerstitial nephritis (TIN) is characterized by immune-mediated tubular injury and requires immunosuppressive therapy. However, diagnosing TIN and assessing therapeutic response are challenging for clinicians due to the lack of useful biomarkers. Pathologically, CD4+T cells infiltrate to renal tubulointerstitium, and soluble interleukin-2 receptor (sIL-2R) has been widely known as a serological marker of activated T cell. Here, we explored the usefulness of serum sIL-2R to predict the treatment outcome in patients with autoimmune TIN.MethodsStudy Design: Single-center retrospective observational study.Participants62 patients were diagnosed of TIN from 2005 to April 2018 at Hokkaido University Hospital. Among them, 30 patients were diagnosed with autoimmune TIN and treated with corticosteroids. We analyzed the association between baseline characteristics including sIL-2R and the change of estimated glomerular filtration rate (eGFR) after initiation of corticosteroids.ResultsThe serum sIL-2R level in patients with autoimmune TIN was significantly higher than that in chronic kidney disease patients with other causes. Mean eGFR in autoimmune TIN patients treated with corticosteroids increased from 43.3 ± 20.4 mL/min/1.73 m2(baseline) to 50.7 ± 19.9 mL/min/1.73 m2(3 months) (ΔeGFR; 22.8 ± 26.0%). Multivariate analysis revealed that higher sIL-2R (per 100 U/mL, β = 1.102,P< 0.001) level was independently associated with the renal recovery. In ROC analysis, sIL-2R had the best area under the curve value (0.805) and the cutoff point was 1182 U/mL (sensitivity = 0.90, 1-specificity = 0.45).ConclusionsOur study showed that elevated serum sIL-2R levels might become a potential predictive marker for therapeutic response in autoimmune TIN.
  • IgA nephropathy preceded by erythroderma with eosinophilia
    Takatsu, Mina; Natsuga, Ken; Hattanda, Fumihiko; Ujiie, Hideyuki
    European Journal of Dermatology, 32, 127, 129, John Libbey Eurotext, 2022年01月01日
  • 本邦における常染色体優性多発性嚢胞腎の予後因子の探索
    麻生 里佳; 西尾 妙織; 八反田 文彦; 島田 幸輝; 中川 直樹; 吉川 純平; 関 豊和; 中沢 大悟; 渥美 達也
    日本腎臓学会誌, 63, 4, 503, 503, (一社)日本腎臓学会, 2021年06月
    日本語
  • Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection
    Kanako Watanabe-Kusunoki; Daigo Nakazawa; Yoshihiro Kusunoki; Takashi Kudo; Fumihiko Hattanda; Saori Nishio; Sakiko Masuda; Utano Tomaru; Takeshi Kondo; Tatsuya Atsumi; Akihiro Ishizu
    Journal of Autoimmunity, 108, 102390, Elsevier BV, 2020年03月
    研究論文(学術雑誌), Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by necrotizing vasculitis with the presence of pathogenic ANCA. ANCA can potentially cause neutrophil activation and induce neutrophil extracellular traps (NETs), resulting in endothelial damage as well as activation of autoreactive B cells and alternative complement pathway. Recombinant thrombomodulin (rTM) protects the endothelium from vascular injury during disseminated intravascular coagulation, thus we hypothesized that rTM ameliorates necrotizing vasculitis in AAV. In this study, rTM was administered in an experimental AAV rat model. Treatment of experimental AAV rats with rTM improved pulmonary hemorrhage and glomerulonephritis, with a suppression of ANCA production and NETs formation. In addition, in vitro experiments showed that rTM bound to neutrophils via Mac-1 (macrophage-1 antigen) and inhibited ANCA-induced NETs formation accompanied by a suppression of histone citrullination, leading to a protection of the endothelium from NETs toxicity. Additionally, rTM affected lymphocytes leading to the inhibition of pro-inflammatory cytokine/chemokin in PBMC during the antibody production process, which might indirectly be involved in the reduction of pathogenic ANCA. Our data revealed that the rTM could ameliorate autoimmune vasculitis through a combination of different biological mechanisms.
  • The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis
    Hattanda, Fumihiko; Nakazawa, Daigo; Watanabe-Kusunoki, Kanako; Kusunoki, Yoshihiro; Shida, Haruki; Masuda, Sakiko; Nishio, Saori; Tomaru, Utano; Atsumi, Tatsuya; Ishizu, Akihiro
    Rheumatology, 58, 7, 1293, 1298, 2019年07月01日
    英語, 研究論文(学術雑誌), Objective Although anti-neutrophil cytoplasmic antibody (ANCA) is the major autoantibody in patients with ANCA-associated vasculitis (AAV), previous studies have suggested the presence of anti-neutrophil extracellular trap (NET) antibody in patients with microscopic polyangiitis (MPA), one type of AAV. In this study, we aimed to determine the prevalence and pathogenic role of anti-NET antibody (ANETA) in MPA. Methods We examined the presence or absence of ANETA in sera obtained from 19 MPA patients by indirect immunofluorescence. We compared the clinical parameters, including age, sex, myeloperoxidase (MPO)-ANCA, creatinine, C-reactive protein, MPO-DNA complexes, and vasculitis activity, in ANETA-positive and ANETA-negative MPA patients. We investigated the serum NET induction and degradation abilities of ANETA-positive and ANETA-negative MPA patients with reference to healthy controls (n=8). Furthermore, we assessed the relationship of ANETA with the effect of IgG depletion on the serum NET degradation ability. Results ANETA was present in 10 of the 19 MPA patients. There was no significant difference in the clinical parameters in ANCA-positive and ANCA-negative MPA patients. Although the NET induction ability was higher and the NET degradation ability was lower in MPA sera than those in healthy controls, these abilities were not different between ANETA-positive and ANETA-negative MPA sera. Interestingly, the NET degradation ability in some sera with ANETA was markedly increased by IgG depletion. Conclusion Some MPA patients produce ANETA and some ANETA possess an inhibitory function against the serum NET degradation ability. Although further studies are needed, ANETA is worthy of attention for understanding the pathophysiology of MPA.
  • A case report dysregulated neutrophil extracellular traps in a patient with propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
    Yuichiro Fujieda; Kanako Watanabe-Kusunoki; Saori Nishio; Nobuya Abe; Tatsuya Atsumi; Fumihiko Hattanda; Daigo Nakazawa; Shinsuke Yasuda; Kohei Karino; Akihiro Ishizu
    Medicine, 98, e15328, Ovid Technologies (Wolters Kluwer Health), 2019年04月01日
    Abstract Rationale: Neutrophil extracellular traps (NETs) are immune defence systems that release extracellular chromatin and myeloid granules including myeloperoxidase (MPO) to kill pathogens. An experimental animal study recently demonstrated that disordered NETs induced by propylthiouracil (PTU) could contribute to the production of MPO anti-neutrophil cytoplasmic antibody (ANCA) and the development of ANCA-associated vasculitis (AAV). However, the role of dysregulated NETs in the pathogenesis of human AAV remains unclear. Patient concerns: We report a 19-year-old woman with Graves’ disease on PTU presented fever, polyarthralgia, and lung hemorrhage with high titer of MPO-ANCA. This patient had a variety of atypical ANCAs and disordered NETs in vitro. Diagnoses: A diagnosis of PTU-induced AAV (PTU-AAV). Interventions: The PTU was discontinued and she was treated with immunosuppressants and plasmapheresis for reducing pathogenic autoantibodies. Outcomes: Clinical manifestations including fever, polyarthralgia, and lung hemorrhage were on remission with a decrease of dysregulated NETs. Lessons: The clinical course of this PTU-AAV case indicated that dysregulated NETs would play a role in the development of ANCA and the pathogenesis of AAV.
  • Initial experience with the use of tris-acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver
    Yusuke Sakuhara; Saori Nishio; Fumihiko Hattanda; Takeshi Soyama; Bunya Takahashi; Daisuke Abo; Hidefumi Mimura
    Clinical and Experimental Nephrology, 23, 6, 825, 833, Springer Science and Business Media LLC, 2019年02月15日
    研究論文(学術雑誌), To assess the safety and effectiveness of transcatheter arterial embolization (TAE) with tris-acryl gelatin microspheres for patients with symptomatic enlarged polycystic liver disease (PCLD).This prospective study was approved by our hospital's institutional review board and planned for patients with symptoms related to enlarged PCLD, such as distended abdomen, gastrointestinal obstruction and abdominal pain. Hemi-hepatic embolization with tris-acryl gelatin microspheres was performed in the hepatic artery supplying the hepatic lobe that showed the predominant presence of cysts. Each patient underwent an assessment of liver function, a questionnaire survey about symptoms, measurement of the estimated volume of the whole liver before and after TAE, and an assessment of complications associated with TAE.Five patients (four females, one male; mean age 52.6 ± 9.1 years) were treated. All five patients successfully completed TAE. The left lobe was treated in three patients and the right in two. After TAE, post-embolization syndrome and transient elevation of white blood cells, aspartate aminotransferase, and alanine aminotransferase occurred in all patients, but none developed hepatic insufficiency or severe complications. The mean whole liver volume was 7406 ± 2323 mL before TAE, and 6995 ± 2139 mL (95.1 ± 5.2% of the pre-therapeutic value) at 3 months and 6855 ± 2246 mL (93.3 ± 9.7%) at 12 months after TAE. Three of the five patients reported an improvement of clinical symptoms within 12 months after TAE.TAE with microspheres can be a safe and effective treatment for symptomatic enlarged PCLD.
  • The Diagnostic and Clinical Utility of the Myeloperoxidase–DNA Complex as a Biomarker in Otitis Media With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
    Shinya Morita; Yuji Nakamaru; Daigo Nakazawa; Masanobu Suzuki; Kimiko Hoshino; Atsushi Fukuda; Fumihiko Hattanda; Kanako Kusunoki; Utano Tomaru; Akihiro Ishizu; Akihiro Homma
    Otology & Neurotology, 40, 2, e99, e106, Ovid Technologies (Wolters Kluwer Health), 2019年02月
    研究論文(学術雑誌),
    Objective:
    This prospective study aimed to evaluate the diagnostic and clinical utility of the myeloperoxidase (MPO)–DNA complex as a NETosis-derived product in the middle ear fluid of patients with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV).


    Study Design:
    Prospective study.


    Setting:
    Tertiary referral center.


    Patients:
    Twenty-two patients diagnosed with OMAAV.


    Intervention:
    Collection of the fluid samples from middle ear.


    Main Outcome Measure:
    The levels of the MPO–DNA complex in the fluid samples were quantified using an enzyme-linked immunosorbent assay.


    Results:
    Patients with both systemic and localized forms of OMAAV showed significantly higher levels of the MPO–DNA complex compared to the controls (p < 0.001 and p = 0.002, respectively). In particular, they showed significantly higher levels of MPO–DNA complex compared to the controls, regardless of serum antineutrophil cytoplasmic antibody status (p < 0.001 and p < 0.001, respectively) or immunosuppressive therapy (p < 0.001 and p < 0.001, respectively) at the time of sampling. An optical density cutoff value of 0.16 at 405 nm according to the receiver operating characteristic curve showed a sensitivity of 86.4%, specificity of 95.5%, positive predictive value of 95.0% and negative predictive value of 87.5% for the diagnosis of OMAAV. Significant positive correlations were observed between the levels of MPO–DNA complex and the values for air conduction – (r = 0.49, p = 0.022) and bone conduction – pure tone average thresholds (r = 0.45, p = 0.035).


    Conclusions:
    The detection and quantification of the MPO–DNA complex in the otitis media fluid may aid in providing a definite diagnosis as well as predicting the activity and severity of OMAAV.
  • Detection of Autoreactive Type II NKT Cells: A Pilot Study of Comparison Between Healthy Individuals and Patients with Vasculitis.
    Nishioka, Yusuke; Sonoda, Takaomi; Shida, Haruki; Kusunoki, Yoshihiro; Hattanda, Fumihiko; Tanimura, Shun; Uozumi, Ryo; Yamada, Mai; Nishibata, Yuka; Masuda, Sakiko; Nakazawa, Daigo; Tomaru, Utano; Atsumi, Tatsuya; Ishizu, Akihiro
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 93, 11, 1157, 1164, 2018年11月
    英語, 研究論文(学術雑誌), NKT cells are defined as T cells that recognize hydrophobic antigens presented by class I MHC-like molecules, including CD1d. Among CD1d-restricted NKT cells, type I and type II subsets have been noted. CD1d-restricted type I NKT cells are regarded as pro-inflammatory cells in general. On the contrary, accumulated evidence has demonstrated an anti-inflammatory property of CD1d-restricted type II NKT cells. In our earlier study using a rat model with vasculitis, we demonstrated the pro-inflammatory function of CD1d-restricted type II NKT cells and identified that one such cell recognized P
  • Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report
    Shida, Haruki; Hashimoto, Nobuhiro; Kusunoki, Yoshihiro; Hattanda, Fumihiko; Ogawa, Yayoi; Hayashi, Terumasa; Nakazawa, Daigo; Masuda, Sakiko; Tomaru, Utano; Ishizu, Akihiro
    BMC nephrology, 19, 145, 2018年06月22日
    英語, 研究論文(学術雑誌), Background: Neutrophil extracellular traps (NETs) are web-like DNA decorated with antimicrobial proteins, such as myeloperoxidase (MPO), which are extruded from activated neutrophils. Although NETs are essential in innate immunity, an excessive formation of NETs has adverse effects, e.g., induction of anti-neutrophil cytoplasmic antibody (ANCA), to the hosts. Since ANCA can induce NET formation in the primed neutrophils, a positive feedback loop can be formed between NETs and ANCA, which is called "ANCA-NETs vicious cycle." Case presentation: A 79-year-old Japanese woman developed hydralazine-induced pauci-immune necrotizing crescentic glomerulonephritis with MPO-ANCA. Although the illness improved after cessation of hydralazine, MPO-ANCA-associated vasculitis relapsed 16 months later. Remission was achieved 5 months after beginning of administration of prednisone. In order to determine the involvement of ANCA-NETs vicious cycle in this patient, we examined NET degradation and induction activities in sera obtained at the disease onset (Serum A; MPO-ANCA, 107 IU/ml), at relapse (Serum B; MPO-ANCA, 195 IU/ml), at 3 months after treatment (Serum C; MPO-ANCA, 4.5 IU/ml), and at remission (Serum D; MPO-ANCA, 2.4 IU/ml). NET degradation activity was low in the all sera. NET induction activity was high in Sera A, B, and C but not in D. Additionally, we demonstrated the presence of anti-NET antibody (ANETA) in Sera B and C but not in A or D. Conclusions: The collective findings suggest NET induction potential of ANETA in the present patient and that the ANETA could contribute to the enhancement of NETs resulting in amplification of the ANCA-NETs vicious cycle.
  • Elevated Level of Myeloperoxidase-Deoxyribonucleic Acid Complex in the Middle Ear Fluid Obtained From Patients With Otitis Media Associated With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
    Shinya Morita; Yuji Nakamaru; Daigo Nakazawa; Fumihiko Hattanda; Haruki Shida; Yoshihiro Kusunoki; Kanako Watanabe; Sakiko Masuda; Dai Takagi; Masanobu Suzuki; Kimiko Hoshino; Atsushi Fukuda; Utano Tomaru; Akihiro Homma; Akihiro Ishizu
    Otology & Neurotology, 39, 4, e257, e262, Ovid Technologies (Wolters Kluwer Health), 2018年04月

    Objective:
    The purpose was to explore the presence of myeloperoxidase (MPO)-deoxyribonucleic acid (DNA) complex as a surrogate marker of neutrophil extracellular traps (NETs) in the middle ear fluid, and to clarify the correlation between its quantifiable level and hearing outcome in patients with otitis media associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).


    Study Design:
    Prospective study.


    Setting:
    Tertiary referral center.


    Patients:
    Nine AAV patients presenting with otitis media.


    Intervention:
    Collection of the fluid samples from middle ear.


    Main Outcome Measure:
    The quantifiable levels of MPO-DNA complex using an enzyme-linked immunosorbent assay.


    Results:
    The quantifiable levels of MPO-DNA complex in patients with AAV were significantly higher than those in controls (p < 0.001). In particular, both ANCA-positive and -negative cases indicated higher levels of MPO-DNA complex compared with the controls (p = 0.004 and p = 0.006, respectively). The significant negative correlations were observed between the level of MPO-DNA complex and the functional hearing values for air (r = −0.82, p = 0.009) and bone conduction (r = −0.73, p = 0.028), respectively.


    Conclusion:
    This analysis is the first to reveal the presence of elevated levels of MPO-DNA complex in the middle ear fluid, suggesting the pathogenic role of NETs in otitis media associated with AAV. NETs may be a valuable biomarker for use in clinical decision-making and predicting hearing outcome, regardless of ANCA status.
  • Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease
    Junya Yamamoto; Saori Nishio; Fumihiko Hattanda; Daigo Nakazawa; Toru Kimura; Michio Sata; Minoru Makita; Yasunobu Ishikawa; Tatsuya Atsumi
    Kidney International, 92, 2, 377, 387, Elsevier BV, 2017年08月
    研究論文(学術雑誌), Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive development of kidney and liver cysts. The mammalian target of rapamycin (mTOR) cascade is one of the important pathways regulating cyst growth in ADPKD. Branched-chain amino acids (BCAAs), including leucine, play a crucial role to activate mTOR pathway. Therefore, we administered BCAA dissolved in the drinking water to Pkd1
  • The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation
    Shida, Haruki; Nakazawa, Daigo; Tateyama, Yu; Miyoshi, Arina; Kusunoki, Yoshihiro; Hattanda, Fumihiko; Masuda, Sakiko; Tomaru, Utano; Kawakami, Tamihiro; Atsumi, Tatsuya; Ishizu, Akihiro
    Frontiers in Immunology, 7, 636, 2016年12月23日
    英語, 研究論文(学術雑誌), Lactoferrin (Lf) is one of the antigens of antineutrophil cytoplasmic antibodies (ANCA) and functions as an endogenous suppressor of neutrophil extracellular trap (NET) formation. However, the prevalence and pathogenicity of anti-lactoferrin antibodies (aLf) in ANCA-associated vasculitis (AAV) remain unrevealed. This study aimed to examine the significance of aLf in AAV, initially. Sixty-five sera from AAV patients, including 41 microscopic polyangiitis, 5 granulomatosis with polyangiitis, and 19 eosinophilic granulomatosis with polyangiitis (EGPA) patients, were subjected to aLf detection using enzyme-linked immunosorbent assay. Clinical characteristics were compared between aLf-positive and aLf-negative patients. Neutrophils from healthy donors were exposed to suboptimal dose (10 nM) of phorbol myristate acetate (PMA) with aLf followed by evaluation of NET formation. Results demonstrated that 4 out of 65 AAV sera (6.2%) were positive for aLf. All of them were EGPA sera (4/19, 21.1%). In EGPA, the frequency of renal involvement, serum CRP levels, and Birmingham Vasculitis Activity Score (BVAS) in the aLf-positive patients was significantly higher than those in the aLf-negative patients, and the aLf titer correlated positively with the serum CRP level and BVAS. The NET formation was particularly enhanced by combined stimulation of 10 nM PMA and 1 µg/mL aLf. IgG isolated from sera of the aLf-positive EGPA patients (250 µg/mL) enhanced NET formation induced by 10 nM of PMA, and the effect was abolished completely by absorption of the aLf. This pilot study suggests that aLf enhance NET formation induced by PMA and are associated with disease activity of EGPA.
  • Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production
    Kusunoki, Yoshihiro; Nakazawa, Daigo; Shida, Haruki; Hattanda, Fumihiko; Miyoshi, Arina; Masuda, Sakiko; Nishio, Saori; Tomaru, Utano; Atsumi, Tatsuya; Ishizu, Akihiro
    Frontiers in Immunology, 7, 227, 2016年06月08日
    英語, 研究論文(学術雑誌), Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis is a systemic small-vessel vasculitis, wherein, MPO-ANCA plays a critical role in the pathogenesis. Neutrophil extracellular traps (NETs) released from activated neutrophils are composed of extracellular web-like DNA and antimicrobial proteins, including MPO. Diverse stimuli, such as phorbol myristate acetate (PMA) and ligands of toll-like receptors (TLR), induce NETs. Although TLR-mediated NET formation can occur with preservation of living neutrophilic functions (called vital NETosis), PMA-stimulated neutrophils undergo cell death with NET formation (called suicidal NETosis). In the process of suicidal NETosis, histones are citrullinated by peptidylarginine deiminase 4 (PAD4). Since this step is necessary for decondensation of DNA, PAD4 plays a pivotal role in suicidal NETosis. Although NETs are essential for elimination of microorganisms, excessive formation of NETs has been suggested to be implicated in MPO-ANCA production. This study aimed to determine if pan-PAD inhibitors could suppress MPO-ANCA production in vivo. At first, NETs were induced in peripheral blood neutrophils derived from healthy donors (1 × 106/ml) by stimulation with 20 nM PMA with or without 20 μM propylthiouracil (PTU), an anti-thyroid drug. We then determined that the in vitro NET formation was inhibited completely by 200 μM Cl-amidine, a pan-PAD inhibitor. Next, we established mouse models with MPO-ANCA production. BALB/c mice were given intraperitoneal (i.p.) injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks. These mice were divided into two groups; the first group was given daily i.p. injection of PBS (200 μl/day) (n = 13) and the other group with daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7). Two weeks later, citrullination as an indicator of NET formation in the peritoneum and serum MPO-ANCA titer was compared between the two groups. Results demonstrated that citrullination in the peritoneum was significantly reduced in the Cl-amidine-treated mice compared with the vehicle-injected control mice (38% reduction). Additionally, the serum MPO-ANCA titer of the Cl-amidine-treated mice (32.3 ± 31.0 ng/ml) was significantly lower than that in the vehicle-injected mice (132.1 ± 41.6 ng/ml). The collective findings indicate that excessive formation of NETs may be implicated in MPO-ANCA production in vivo.
■ その他活動・業績
■ 所属学協会
  • 日本リウマチ学会
  • 多発性嚢胞腎協会
  • 日本臨床腎移植学会
  • 日本透析医学会
  • 日本腎臓学会
  • 日本内科学会
■ 共同研究・競争的資金等の研究課題